KR101704665B1 - 환형 테트라펩티드류 및 이들의 치료적 적용 - Google Patents

환형 테트라펩티드류 및 이들의 치료적 적용 Download PDF

Info

Publication number
KR101704665B1
KR101704665B1 KR1020127024471A KR20127024471A KR101704665B1 KR 101704665 B1 KR101704665 B1 KR 101704665B1 KR 1020127024471 A KR1020127024471 A KR 1020127024471A KR 20127024471 A KR20127024471 A KR 20127024471A KR 101704665 B1 KR101704665 B1 KR 101704665B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
formula
pharmaceutically acceptable
linked together
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127024471A
Other languages
English (en)
Korean (ko)
Other versions
KR20130088004A (ko
Inventor
야너스 자브록키
미할 지멕키
안드레이 카수바
츠스토프 카츠마렉
Original Assignee
펩타덤 에스피.지.오.오.
로츠 유니버시티 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펩타덤 에스피.지.오.오., 로츠 유니버시티 오브 테크놀로지 filed Critical 펩타덤 에스피.지.오.오.
Publication of KR20130088004A publication Critical patent/KR20130088004A/ko
Application granted granted Critical
Publication of KR101704665B1 publication Critical patent/KR101704665B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020127024471A 2010-02-19 2011-02-19 환형 테트라펩티드류 및 이들의 치료적 적용 Expired - Fee Related KR101704665B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL390493A PL219569B1 (pl) 2010-02-19 2010-02-19 Cykliczne tetrapeptydy i ich zastosowanie
PLP.390493 2010-02-19
PCT/US2011/025571 WO2011103524A2 (en) 2010-02-19 2011-02-19 Cyclic tetrapeptides and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
KR20130088004A KR20130088004A (ko) 2013-08-07
KR101704665B1 true KR101704665B1 (ko) 2017-02-08

Family

ID=44483608

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127024471A Expired - Fee Related KR101704665B1 (ko) 2010-02-19 2011-02-19 환형 테트라펩티드류 및 이들의 치료적 적용

Country Status (13)

Country Link
US (3) US20130224232A1 (enExample)
EP (1) EP2536732B1 (enExample)
JP (1) JP5901543B2 (enExample)
KR (1) KR101704665B1 (enExample)
CN (1) CN102858779B (enExample)
AU (1) AU2011217882B2 (enExample)
BR (1) BR112012020833A2 (enExample)
CA (1) CA2827694C (enExample)
ES (1) ES2611663T3 (enExample)
IL (2) IL221535A (enExample)
PL (1) PL219569B1 (enExample)
RU (1) RU2568436C2 (enExample)
WO (1) WO2011103524A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
WO2016179398A1 (en) 2015-05-05 2016-11-10 Washington University Isoform-selective lysine deacetylase inhibitors
US10154997B2 (en) 2015-08-04 2018-12-18 Washington University Treatment of parasitic diseases using KDAC inhibitor compounds
WO2018232285A1 (en) * 2017-06-16 2018-12-20 University Of Florida Research Foundation, Incorporated Macrocyclic peptides and derivatives thereof with opioid activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216124A (en) 1989-12-15 1993-06-01 G. D. Searle & Co. Substituted cyclic tetrapeptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
IT1077010B (it) * 1976-09-01 1985-04-27 Snam Progetti Processo per la preparazione di copolimeri dell isobutilene contenenti insaturazioni ed atomi di alogeno reattivi
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
JPH0334991A (ja) * 1989-06-30 1991-02-14 Shionogi & Co Ltd 環状テトラペプチドおよびその製造法
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6013763A (en) 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
DE69926061T2 (de) * 1998-03-23 2006-06-01 Trimeris Inc. Verfahren und zusammensetzungen zur peptidsynthese (t-20)
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
DE19816922A1 (de) 1998-04-16 1999-10-21 Wolfgang Beck Einfache Synthese von cyclischen Tetrapeptiden aus nichtaktivierten Peptidestern an Metallzentren
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
KR20010080142A (ko) 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
GB9903087D0 (en) * 1999-02-12 1999-03-31 Glaxo Group Ltd Process
EP1701969B1 (en) 2003-12-31 2007-10-24 F.Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
WO2006049597A1 (en) 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
US20080219962A1 (en) * 2004-12-14 2008-09-11 Biorunx Co., Ltd. Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation
JP2010502574A (ja) 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用
KR101595138B1 (ko) 2008-02-27 2016-02-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 괴사종양의 광역학요법 및 영상용 알지디(박테리오)클로로필 컨쥬게이트
WO2010006267A2 (en) * 2008-07-11 2010-01-14 University Of Kansas Cyclic tetrapeptides
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216124A (en) 1989-12-15 1993-06-01 G. D. Searle & Co. Substituted cyclic tetrapeptides

Also Published As

Publication number Publication date
US10238713B2 (en) 2019-03-26
CN102858779A (zh) 2013-01-02
JP5901543B2 (ja) 2016-04-13
RU2568436C2 (ru) 2015-11-20
EP2536732B1 (en) 2016-10-19
AU2011217882A1 (en) 2012-10-11
AU2011217882B2 (en) 2015-02-05
WO2011103524A8 (en) 2012-09-13
WO2011103524A3 (en) 2011-12-29
CA2827694C (en) 2018-09-18
PL390493A1 (pl) 2011-08-29
CA2827694A1 (en) 2011-08-25
PL219569B1 (pl) 2015-05-29
US20130108655A1 (en) 2013-05-02
CN102858779B (zh) 2016-08-03
KR20130088004A (ko) 2013-08-07
US20130224232A1 (en) 2013-08-29
US20170157204A1 (en) 2017-06-08
RU2012139668A (ru) 2014-03-27
WO2011103524A2 (en) 2011-08-25
JP2013520440A (ja) 2013-06-06
ES2611663T3 (es) 2017-05-09
IL221535A (en) 2016-08-31
EP2536732A4 (en) 2014-04-30
BR112012020833A2 (pt) 2017-12-19
EP2536732A2 (en) 2012-12-26
IL224410A (en) 2017-07-31
US9382292B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
KR101479148B1 (ko) 주형 고정된 펩타이드 모방체
KR101704665B1 (ko) 환형 테트라펩티드류 및 이들의 치료적 적용
CZ372698A3 (cs) Substituované imidazolidinové deriváty, způsob jejich přípravy, jejich použití a farmaceutické prostředky, které je obsahují
CZ266398A3 (cs) Peptidové deriváty, způsob přípravy a použití
CN105636975B (zh) 抗炎三肽
US12297293B2 (en) Peptide compounds targeting PD-1 receptor as well as preparation and applications thereof
KR20060073618A (ko) 신규 항종양 화합물
AU671118B2 (en) Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
Cebrat et al. Sulfonated analogues of cyclolinopeptide A Synthesis, immunosuppressive activity and CD studies
WO2024037263A1 (zh) 一种体内低毒性的抑制金葡菌毒素产生的合成肽及其应用
Bamoniri et al. Synthesis of cyclic peptide Longicalycinin A analogues by using solid resin
Siemion et al. Peptides related to FKBP 39–45 loop possess immunostimulative potency
NO175102B (no) Analogifremgangsmåte for syntese av tetrapeptidet Ser-Asp-Lys-Pro-OH

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210203

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210203